Corcept Therapeutics Incorporated (FRA:HTD)

Corcept Therapeutics Revenue

Corcept Therapeutics had revenue of $207.64M USD in the quarter ending September 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $741.17M, up 17.92% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.

• Revenue (ttm): $741.17M
• Revenue Growth: +17.92%
• P/S Ratio: 11.43
• Revenue / Employee: $1.48M
• Employees: 500
• Market Cap: 7.22B EUR

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	675.04M	192.67M	39.94%
Dec 31, 2023	482.38M	80.52M	20.04%
Dec 31, 2022	401.86M	35.88M	9.80%
Dec 31, 2021	365.98M	12.10M	3.42%
Dec 31, 2020	353.87M	47.39M	15.46%
Dec 31, 2019	306.49M	55.24M	21.99%
Dec 31, 2018	251.25M	92.05M	57.82%
Dec 31, 2017	159.20M	77.88M	95.77%
Dec 31, 2016	81.32M	31.04M	61.72%
Dec 31, 2015	50.29M	23.74M	89.39%
Dec 31, 2014	26.55M	16.19M	156.36%
Dec 31, 2013	10.36M	7.05M	213.18%
Dec 31, 2012	3.31M	-	-
Dec 31, 2011	-	-	-
Dec 31, 2010	-	-	-
Dec 31, 2009	29.00K	-180.00K	-86.12%
Dec 31, 2008	209.00K	-273.00K	-56.64%
Dec 31, 2007	482.00K	188.00K	63.95%
Dec 31, 2006	294.00K	-	-
Dec 31, 2005	-	-	-